To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Prospective, Open-labeled, 1 Year Extension Study of the Efficacy and the Safety During Treatment of Tocilizumab in Patients With Active RA Completing Treatment CWP-TCZ301 Study

The purpose of this study is to evaluate 1 year extension study of the efficacy and the safety during treatment tocilizumab in patients completing treatment CWP-TCZ301 study with moderate to severe active RA and an inadequate response to current DMARD.

Inclusion Criteria:

• Patients Who have been satisfied the in/exclusion criteria of CWP-TCZ301
• Patients who have been withdrawn after receiving escape therapy or completed treatment during 24weeks in CWP-TCZ301 study
• Patients who able to enroll in this study within 12 weeks after last infusion of CWP-TCZ301
• Willing to give written informed consent

Exclusion Criteria:

• History of severe allergic or anaphylactic reactions to Investigational product in CWP-TCZ301 study
• ALT or AST > ULNⅹ2.5
• Platelet count < 100ⅹ103/ μL
• WBC < 3,000/mm3
• Absolute neutrophil count < 1,000/mm3
• Absolute lymphocyte count < 500/mm3
• Total bilirubin > ULNⅹ2